312 related articles for article (PubMed ID: 33834631)
1. Leukemic stem cells shall be searched in the bone marrow before "tyrosine kinase inhibitor-discontinuation" in chronic myeloid leukemia.
Ilhan O; Narli Ozdemir Z; Dalva K; Arslan A; Okay Ozgeyik M; Ipek S; Saydam G; Haznedaroglu IC
Int J Lab Hematol; 2021 Oct; 43(5):1110-1116. PubMed ID: 33834631
[TBL] [Abstract][Full Text] [Related]
2. Overcoming BCR::ABL1 dependent and independent survival mechanisms in chronic myeloid leukaemia using a multi-kinase targeting approach.
Busch C; Mulholland T; Zagnoni M; Dalby M; Berry C; Wheadon H
Cell Commun Signal; 2023 Nov; 21(1):342. PubMed ID: 38031192
[TBL] [Abstract][Full Text] [Related]
3. Flow Cytometry Assessment of CD26
Raspadori D; Pacelli P; Sicuranza A; Abruzzese E; Iurlo A; Cattaneo D; Gozzini A; Galimberti S; Baratè C; Pregno P; Nicolosi M; Sorà F; Annunziata M; Luciano L; Caocci G; Moretti S; Sgherza N; Fozza C; Russo S; Usala E; Liberati MA; Ciofini S; Trawinska MM; Gozzetti A; Bocchia M
Cytometry B Clin Cytom; 2019 Jul; 96(4):294-299. PubMed ID: 30714299
[TBL] [Abstract][Full Text] [Related]
4. Bone marrow niche trafficking of miR-126 controls the self-renewal of leukemia stem cells in chronic myelogenous leukemia.
Zhang B; Nguyen LXT; Li L; Zhao D; Kumar B; Wu H; Lin A; Pellicano F; Hopcroft L; Su YL; Copland M; Holyoake TL; Kuo CJ; Bhatia R; Snyder DS; Ali H; Stein AS; Brewer C; Wang H; McDonald T; Swiderski P; Troadec E; Chen CC; Dorrance A; Pullarkat V; Yuan YC; Perrotti D; Carlesso N; Forman SJ; Kortylewski M; Kuo YH; Marcucci G
Nat Med; 2018 May; 24(4):450-462. PubMed ID: 29505034
[TBL] [Abstract][Full Text] [Related]
5. Residual Peripheral Blood CD26
Bocchia M; Sicuranza A; Abruzzese E; Iurlo A; Sirianni S; Gozzini A; Galimberti S; Aprile L; Martino B; Pregno P; Sorà F; Alunni G; Fava C; Castagnetti F; Puccetti L; Breccia M; Cattaneo D; Defina M; Mulas O; Baratè C; Caocci G; Sica S; Gozzetti A; Luciano L; Crugnola M; Annunziata M; Tiribelli M; Pacelli P; Ferrigno I; Usala E; Sgherza N; Rosti G; Bosi A; Raspadori D
Front Oncol; 2018; 8():194. PubMed ID: 29900128
[TBL] [Abstract][Full Text] [Related]
6. Leukemic stem cell persistence in chronic myeloid leukemia patients in deep molecular response induced by tyrosine kinase inhibitors and the impact of therapy discontinuation.
Chomel JC; Bonnet ML; Sorel N; Sloma I; Bennaceur-Griscelli A; Rea D; Legros L; Marfaing-Koka A; Bourhis JH; Ame S; Guerci-Bresler A; Rousselot P; Turhan AG
Oncotarget; 2016 Jun; 7(23):35293-301. PubMed ID: 27167108
[TBL] [Abstract][Full Text] [Related]
7. Microenvironmental protection of CML stem and progenitor cells from tyrosine kinase inhibitors through N-cadherin and Wnt-β-catenin signaling.
Zhang B; Li M; McDonald T; Holyoake TL; Moon RT; Campana D; Shultz L; Bhatia R
Blood; 2013 Mar; 121(10):1824-38. PubMed ID: 23299311
[TBL] [Abstract][Full Text] [Related]
8. Identification of peripheral blood CD26+ leukemic stem cells has a potential role in the rapid diagnosis of chronic myeloid leukemia.
Sharma P; Sachdeva MUS; Naseem S; Sreedharanunni S; Das R; Malhotra P; Varma N
Int J Lab Hematol; 2022 Jun; 44(3):518-523. PubMed ID: 35142061
[TBL] [Abstract][Full Text] [Related]
9. Leukemic Stem Cell Quantification in Newly Diagnosed Patients With Chronic Myeloid Leukemia Predicts Response to Nilotinib Therapy.
Thielen N; Richter J; Baldauf M; Barbany G; Fioretos T; Giles F; Gjertsen BT; Hochhaus A; Schuurhuis GJ; Sopper S; Stenke L; Thunberg S; Wolf D; Ossenkoppele G; Porkka K; Janssen J; Mustjoki S
Clin Cancer Res; 2016 Aug; 22(16):4030-8. PubMed ID: 27006491
[TBL] [Abstract][Full Text] [Related]
10. TNF-α-induced alterations in stromal progenitors enhance leukemic stem cell growth via CXCR2 signaling.
Agarwal P; Li H; Choi K; Hueneman K; He J; Welner RS; Starczynowski DT; Bhatia R
Cell Rep; 2021 Jul; 36(2):109386. PubMed ID: 34260914
[TBL] [Abstract][Full Text] [Related]
11. Nilotinib-induced bone marrow CD34+/lin-Ph+ cells early clearance in newly diagnosed CP-Chronic Myeloid Leukemia: Final report of the PhilosoPhi34 study.
Pungolino E; D'adda M; De Canal G; Trojani A; Perego A; Elena C; Lunghi F; Turrini M; Borin L; Iurlo A; Latargia ML; Carraro MC; Spina F; Artale S; Anghilieri M; Molteni A; Caramella M; Baruzzo G; Nichelatti M; Di Camillo B; Cairoli R
Eur J Haematol; 2021 Oct; 107(4):436-448. PubMed ID: 34139044
[TBL] [Abstract][Full Text] [Related]
12. Preservation of Quiescent Chronic Myelogenous Leukemia Stem Cells by the Bone Marrow Microenvironment.
Shah M; Bhatia R
Adv Exp Med Biol; 2018; 1100():97-110. PubMed ID: 30411262
[TBL] [Abstract][Full Text] [Related]
13. Chronic myeloid leukemia stem cells.
Houshmand M; Simonetti G; Circosta P; Gaidano V; Cignetti A; Martinelli G; Saglio G; Gale RP
Leukemia; 2019 Jul; 33(7):1543-1556. PubMed ID: 31127148
[TBL] [Abstract][Full Text] [Related]
14. beta-Catenin is essential for survival of leukemic stem cells insensitive to kinase inhibition in mice with BCR-ABL-induced chronic myeloid leukemia.
Hu Y; Chen Y; Douglas L; Li S
Leukemia; 2009 Jan; 23(1):109-16. PubMed ID: 18818703
[TBL] [Abstract][Full Text] [Related]
15. Minimal Residual Disease Detection at RNA and Leukemic Stem Cell (LSC) Levels: Comparison of RT-qPCR, d-PCR and CD26+ Stem Cell Measurements in Chronic Myeloid Leukemia (CML) Patients in Deep Molecular Response (DMR).
Abruzzese E; Bocchia M; Trawinska MM; Raspadori D; Bondanini F; Sicuranza A; Pacelli P; Re F; Cavalleri A; Farina M; Malagola M; Russo D; De Fabritiis P; Bernardi S
Cancers (Basel); 2023 Aug; 15(16):. PubMed ID: 37627140
[TBL] [Abstract][Full Text] [Related]
16. Deregulated expression of miR-29a-3p, miR-494-3p and miR-660-5p affects sensitivity to tyrosine kinase inhibitors in CML leukemic stem cells.
Salati S; Salvestrini V; Carretta C; Genovese E; Rontauroli S; Zini R; Rossi C; Ruberti S; Bianchi E; Barbieri G; Curti A; Castagnetti F; Gugliotta G; Rosti G; Bergamaschi M; Tafuri A; Tagliafico E; Lemoli R; Manfredini R
Oncotarget; 2017 Jul; 8(30):49451-49469. PubMed ID: 28533480
[TBL] [Abstract][Full Text] [Related]
17. Delineation of target expression profiles in CD34+/CD38- and CD34+/CD38+ stem and progenitor cells in AML and CML.
Herrmann H; Sadovnik I; Eisenwort G; Rülicke T; Blatt K; Herndlhofer S; Willmann M; Stefanzl G; Baumgartner S; Greiner G; Schulenburg A; Mueller N; Rabitsch W; Bilban M; Hoermann G; Streubel B; Vallera DA; Sperr WR; Valent P
Blood Adv; 2020 Oct; 4(20):5118-5132. PubMed ID: 33085758
[TBL] [Abstract][Full Text] [Related]
18. Characterization of the bone marrow niche in patients with chronic myeloid leukemia identifies CXCL14 as a new therapeutic option.
Dolinska M; Cai H; Månsson A; Shen J; Xiao P; Bouderlique T; Li X; Leonard E; Chang M; Gao Y; Medina JP; Kondo M; Sandhow L; Johansson AS; Deneberg S; Söderlund S; Jädersten M; Ungerstedt J; Tobiasson M; Östman A; Mustjoki S; Stenke L; Le Blanc K; Hellström-Lindberg E; Lehmann S; Ekblom M; Olsson-Strömberg U; Sigvardsson M; Qian H
Blood; 2023 Jul; 142(1):73-89. PubMed ID: 37018663
[TBL] [Abstract][Full Text] [Related]
19. The Impact of Tyrosine Kinase Inhibitors on Chronic Myeloid Leukemia Stem Cells and the Implication in Discontinuation.
Jiang L; Wang H; Zhu X; Liu W; Zhou S; Geng Z; Xiao Y; Zou P; You Y; Li Q; Zhu X
Stem Cells Dev; 2019 Nov; 28(22):1480-1485. PubMed ID: 31530245
[TBL] [Abstract][Full Text] [Related]
20. Druggable Biochemical Pathways and Potential Therapeutic Alternatives to Target Leukemic Stem Cells and Eliminate the Residual Disease in Chronic Myeloid Leukemia.
Muselli F; Peyron JF; Mary D
Int J Mol Sci; 2019 Nov; 20(22):. PubMed ID: 31717629
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]